Zacks Research Issues Negative Outlook for GSK Earnings

GSK plc (NYSE:GSK - Free Report) - Stock analysts at Zacks Research cut their Q1 2026 EPS estimates for GSK in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings of $1.12 per share for the quarter, down from their prior forecast of $1.14. The consensus estimate for GSK's current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK's Q2 2026 earnings at $1.12 EPS and Q3 2026 earnings at $1.52 EPS.

A number of other equities research analysts have also recently weighed in on the company. Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and dropped their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Guggenheim cut shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday. Finally, Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $43.25.

GSK Trading Down 1.1 %

NYSE GSK traded down $0.37 during trading hours on Monday, reaching $33.58. The company had a trading volume of 4,914,924 shares, compared to its average volume of 4,162,148. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $69.60 billion, a P/E ratio of 22.05, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. The stock has a 50-day moving average of $36.18 and a 200 day moving average of $39.21. GSK has a 1-year low of $32.83 and a 1-year high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from GSK's previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.68%. GSK's dividend payout ratio is 99.35%.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GSK

Several institutional investors and hedge funds have recently added to or reduced their stakes in GSK. Eastern Bank purchased a new position in shares of GSK in the 3rd quarter valued at about $26,000. Sunbelt Securities Inc. increased its holdings in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners increased its holdings in GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock valued at $32,000 after buying an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of GSK during the 2nd quarter valued at approximately $37,000. Finally, Fortitude Family Office LLC acquired a new stake in shares of GSK in the 3rd quarter worth approximately $42,000. Institutional investors and hedge funds own 15.74% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.